Dasatinib shows promise in controlling early CML
NCT ID NCT00254423
First seen Jan 17, 2026 · Last updated May 05, 2026 · Updated 12 times
Summary
This study tested the drug dasatinib in 150 adults with early chronic phase chronic myeloid leukemia (CML) to see if it can control the disease. Participants had been diagnosed within the past year and received little or no prior treatment. The main goal was to see how many achieved a major molecular response (very low levels of cancer genes) after 12 months, and the study also tracked overall survival and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.